Kodiak Sciences (NASDAQ: KOD) just reported positive Phase 3 results for two experimental treatments targeting wet age-related macular degeneration (wet AMD), a serious eye disease that can cause significant vision loss.

‍

In the DAYBREAK study, Kodiak's Zenkuda matched the vision improvements produced by aflibercept, an established treatment for wet AMD. But Zenkuda may have an important advantage: patients could potentially go much longer between injections.

‍

Wet AMD is caused by abnormal blood vessels growing underneath the retina. Those vessels can leak blood and fluid, damaging the part of the eye responsible for sharp central vision.

‍

Current drugs can control the disease, but patients often need repeated injections directly into the eye. That treatment burden can continue for years.

‍

Zenkuda, however, is designed to last longer inside the eye.

‍

Next stop, the FDA

‍

In DAYBREAK, 54% of patients receiving Zenkuda reached a six-month interval between treatments after one year while maintaining disease control. Kodiak also reported vision improvements comparable to aflibercept.

‍

In other words, some patients who currently require injections every few weeks or months could potentially receive treatment only twice a year.

‍

Kodiak's second drug, tabirafusp-ted, also met the study's primary goal. Unlike Zenkuda, which targets a protein called VEGF that contributes to abnormal blood-vessel growth, tabirafusp-ted targets both VEGF and another protein called IL-6, which is associated with inflammation.

‍

Kodiak is now planning additional analyses to determine whether certain wet AMD patients could benefit particularly well from that two-pronged approach.

‍

The company plans to submit an application for FDA approval in the fourth quarter of 2026, backed by five successful Phase 3 studies covering wet AMD, diabetic retinopathy, and retinal vein occlusion.

‍

If approved, Zenkuda could give doctors what they've wanted for years: a treatment that preserves vision while dramatically reducing how often some patients need eye injections.

‍

Meanwhile, the market loved the news.  The stock soared, ending the trading day with a gain of more than 177%.  

‍